Prakt. lékáren. 2020; 16(3): 131-138

Functional bowel disorders and their treatment

Peter Minárik1,2,3, Daniela Mináriková4
1 Ústav zdravotníckych disciplín, Vysoká škola zdravotníctva a sociálnej práce sv. Alžbety, Bratislava
2 II. rádiologická klinika LF UK a OÚSA, Onkologický ústav sv. Alžbety, Bratislava
3 Biomedicínske centrum, Slovenská akadémia vied, Bratislava
4 Katedra organizácie a riadenia farmácie, Farmaceutická fakulta UK, Bratislava

Functional gastrointestinal disorders (FGID) belong to the most common diagnoses in gastroenterology. Functional bowel disorders, especially irritable bowel syndrome, represent an important part of the FGID. The currently valid classification of the FGID is the Rome IV classification from the year 2016 (Rome IV). In differential diagnosis of gastrointestinal disorders, it is always important to distinguish functional disorders from severe organic diseases of the gastrointestinal tract, especially from tumor diseases. Significant role in differential diagnostics and follow-up analysis play the alarm symptoms. This article deals with the review and analysis of functional bowel disorders and their treatment options. Complex treatment of functional bowel disorders is based on non-pharmacological and pharmacological methods of therapy. Dominant part of the pharmacological treatment is the chemically defined monotherapy, but appropriate multi-target effects can also be achieved through multi-component phytopharmacon.

Keywords: functional bowel disorders, irritable bowel syndrome, diarrhoea, constipation, medical therapy, phytopharmacotherapy.

Published: October 8, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Minárik P, Mináriková D. Functional bowel disorders and their treatment. Praktické lékárenství. 2020;16(3):131-138.
Download citation

References

  1. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology 2016; 150(6): 1262-1279. Go to original source... Go to PubMed...
  2. Lin LD, Chang L. Using the Rome IV Criteria to Help Manage the Complex IBS Patient. Am J Gastroenterol. 2018; 113(4): 453-456. doi: 10.1038/ajg.2017.477. Go to original source... Go to PubMed...
  3. Schmulson MJ, Drossman DA. What Is New in Rome IV. J Neurogastroenterol Motil. 2017; 23(2): 151-163. Go to original source... Go to PubMed...
  4. Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain interaction. Gastroenterology 2016; 150(6): 1257-1261. Go to original source... Go to PubMed...
  5. Drossman DA, Thomson WG, Talley NJ, et al. Identification of subgroups of functional bowel disorders. Gastroenterol Int. 1990; 3: 159-172.
  6. Mearin F, Lacy BE, Chang L, et al. The Rome IV Committees, eds. Rome IV functional gastrointestinal disorders - disorders of gut-brain interaction. Volume II. Raleigh, NC: The Rome Foundation; 2016: 967-1057.
  7. Lacy BE, Patel NK. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J. Clin. Med. 2017; 26,6(11). doi: 10.3390/jcm6110099. Go to original source... Go to PubMed...
  8. Seifert B, Lukáš K, Charvátová E, et al. Dolní dyspeptický syndrom. Doporučený diagnosticky a léčebný postup pro všeobecné praktické lékaře. Centrum doporučených postupú pro praktické lékaře. CDP-PL. Praha: Společnost všeobecního lékařství; 2007: 1-7.
  9. Huorka M. Čo všetko sa môže skrývať pod pojmom horný dyspeptický syndróm (prekrývanie - overlap symptómov). Gastroenterol. prax. 2018; 17(2): 93-96.
  10. Mego M, Zajac V. Probiotiká a ochorenia tráviaceho traktu. Ambulantná terapia 2008; 6(3): 192-197.
  11. Klucho J. Colon irritabile - IBS a liečba probiotikami. Via pract. 2018; 15(1): 46-48.
  12. Minárik P, Mináriková D. Úloha probiotík pri udržiavaní zdravého tráviaceho a imunitného systému. Prakt. lekárn. 2017; 7(2): 66-70.
  13. Konečný M, Ehrmann J. Liečba dráždivého čreva [online]. 2014. Dostupné na . Accessed February 28, 2019.
  14. Madisch A, Andresen V, Enck P, et al. The Diagnosis and Treatment of Functional Dyspepsia. Dtsch Arztebl Int. 2018; 115(13): 222-232. Go to original source... Go to PubMed...
  15. Kroll U, Cordes C. Pharmaceutical prerequisites for a multi-target therapy. Phytomedicine 2006; 13: SV12-19. Go to original source... Go to PubMed...
  16. Rösch W, Liebregts T, Gundermann K-J, et al. Phytotherapy for functional dyspepsia: A review of the clinical evidence for the herbal preparation STW 5. Phytomedicine 2006; 13(13): SV114-121. Go to original source... Go to PubMed...
  17. Ammon HPT, Kelber O, Okpanyi SN. Spasmolytic and tonic effect of Iberogast® (STW 5) in intestinal smooth muscle. Phytomedicine 2006; 13: SV67-74. Go to original source... Go to PubMed...




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.